Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The conference will take place at the Hilton Orlando in Orlando, FL from March 3-6, 2024.

Details of the Edgewise presentations at MDA:

Podium Presentation in Clinical Trial Updates Session

Title: Functional and Muscle Damage Biomarker Changes Following Treatment with EDG-5506, a Fast Myosin Modulator, in Adults with Becker Muscular Dystrophy

Dr. Phan’s presentation will include 12-month data from the ARCH trial of EDG-5506.

Presenter: Han C. Phan, M.D., Head of Research & Principal Investigator, Pediatric Neurologist, Rare Disease Research, LLC

Date: Wednesday, March 6, 2024, 11:15 – 11:30 am ET

Scientific Posters

Title: Comparison of Short- and Long-Term Proteomic Response to the Fast Skeletal Myosin Inhibitor, EDG-5506, in Becker Muscular Dystrophy (BMD) (Poster # M145)

Title: North Star (NSAA and NSAD) Functional Assessments in Individuals with Becker Muscular Dystrophy (poster # M147)

A companion poster presentation will be available for Dr. Phan’s presentation (poster # M146). Posters will be showcased during the Networking & Poster Reception in the Exhibit Hall on Monday, March 4, 2024, from 6 – 8 PM ET. The full MDA 2024 Conference program is available here: https://mdaconference.org.

The Edgewise presentation and posters will be available on the Edgewise website when they are presented.

Edgewise Industry Forum with Key Opinion Leaders

On March 4, 2024, at 12 pm ET, Edgewise is sponsoring an Industry Forum, “Protecting and preserving dystrophic muscle: The balance between exercise and contraction-induced muscle injury.” The forum will feature presentations by leading neuromuscular disease experts, John Vissing, M.D., Ph.D., Professor of Neurology, Director Neuromuscular Clinic and Research Unit, Department of Neurology, University of Copenhagen, and Tanja Taivassalo, Ph.D., Associate Professor, Department of Physiology and Aging, University of Florida, as well as Edgewise Chief Medical Officer, Joanne Donovan, M.D., Ph.D. Only registered conference attendees can register for the symposium.